KYM

Global Claudin 18.2 Targeted Therapy Market Opportunity Report 2023-2028: 60 Drugs in Clinical Trial, Insight On Technical & Clinical Development Platforms, Breakdown by Company, Indication & Phase - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Pharmaceutical, Health, Clinical Trials, Drug resistance, Particular, Indication, Medicine, AstraZeneca, Hubli railway division, Antibody, Research, FDA, Malignancy, Hope, Prevalence, Tissue, Clinical trial, Cancer, KYM, Neoplasm, Biomarker, CLDN18, Epithelium, Growth, Patient, Safety, Qingdao University, Gastric mucosa, BLA, Pharmaceutical industry

The "Global Claudin 18.2 Targeted Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Claudin 18.2 Targeted Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Small pharmaceutical companies working on CLDN18-targeting therapies are also becoming more visible in the pharmaceutical market.
  • Therefore, CLDN18 and its variant CLDN18.2 are a ray of hope in the pharmaceutical industry, especially cancer therapy.
  • Claudin 18.2 Targeted Drugs In Clinical Trials: > 60 Drugs
    Global Claudin 18.2 Drugs Clinical Trials By Company, Indication & Phase
    Claudin 18.2 Targeted Therapy Development Approaches: CAR T Cell Therapy, Bispecific Antibodies, Antibody Drug Conjugates

Kym Whitley To Host TMCF’s Leaders & Legends Gala

Retrieved on: 
Friday, September 22, 2023
Master of None, College Road Trip, Bachelor of Science, Thurgood Marshall College Fund, Love, KYM, Lynchburg, Life, Fisk University, The Wayans Bros., Waithe, HBCU, Table, UVA, 47th NAACP Image Awards, L.A, Food, Young & Hungry, Act Your Age, 2 Broke Girls (season 1), Rhythm and blues, Alabama State University, Neighbourhood, Parkers, Thurgood Marshall College, TIAA, Naismith Memorial Basketball Hall of Fame, For Love, HBO Max, NBA, OWN, Raising Whitley, The Parkers, Along Came Polly, The Upshaws, Thurgood Marshall, Wells Fargo, Netflix, Gala, Leadership Institute, Television, Management, Film industry, Science

WASHINGTON, D.C., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Actress and comedian Kym Whitley will serve as host of the Thurgood Marshall College Fund’s 36th Annual “Leaders and Legends” Fundraising Gala on Saturday, September 23, 2023 at the Washington, D.C. Hilton Hotel.

Key Points: 
  • WASHINGTON, D.C., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Actress and comedian Kym Whitley will serve as host of the Thurgood Marshall College Fund’s 36th Annual “Leaders and Legends” Fundraising Gala on Saturday, September 23, 2023 at the Washington, D.C. Hilton Hotel.
  • “We are grateful for Kym Whitley’s willingness to host our annual gala,” TMCF CEO & President Harry L. Williams said.
  • “As a HBCU graduate, Kym understands the mission of TMCF and how we work hard to continue the work of Justice Thurgood Marshall.
  • Whitley starred in her own docu-series, Raising Whitley on the OWN network, and in Netflix’s sitcom, Young & Hungry.

Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

Retrieved on: 
Thursday, February 23, 2023
Medicine, Safety, Senior, Gastrointestinal cancer, Research, KYM, Patient, HK, AstraZeneca, ADC, Pharmaceutical industry, KeyMe

CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC).

Key Points: 
  • CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC).
  • Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of  CMG901 globally.
  • CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors.
  • The global scope of this agreement has the potential to benefit patients in China, and throughout the world."

Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

Retrieved on: 
Thursday, February 23, 2023
Medicine, Safety, Senior, Gastrointestinal cancer, Research, KYM, Patient, HK, AstraZeneca, ADC, Pharmaceutical industry, KeyMe

CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC).

Key Points: 
  • CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC).
  • Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of  CMG901 globally.
  • CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors.
  • The global scope of this agreement has the potential to benefit patients in China, and throughout the world."

CES 2022: KaiKuTeK reveals world's first single system-on-chip contactless 3D gesture recognition system

Retrieved on: 
Friday, July 29, 2022
AIP, Intelligence, Greenidea artocarpi, CES, Industry, Booth, Radar, BOM, Glass, DSP, COVID-19, Machine learning, Marketing, MWC, Align Technology, TWS, SOC, TTA, Exhibition, KYM, AR, Video game, Medical device

TAIPEI, July 29, 2022 /PRNewswire/ -- A wholly-owned subsidiary of JMicron Technology Crop. (https://www.jmicron.com/), Taiwanese startup, KaiKuTeK Inc. (https://www.kaikutek.com), is revolutionizing a post-pandemic world with a game-changing innovation that meets the needs of a low-touch economy. KaiKuTeK has unveiled the world's first contactless gesture recognition system at CES 2022.

Key Points: 
  • ( https://www.jmicron.com/ ), Taiwanese startup, KaiKuTeK Inc. ( https://www.kaikutek.com ), is revolutionizing a post-pandemic world with a game-changing innovation that meets the needs of a low-touch economy.
  • KaiKuTeK has unveiled the world's first contactless gesture recognition system at CES 2022.
  • Key advantages of using millimeter-wave radar technology for gesture recognition include quick response time and higher recognition accuracy.
  • We believe we are initiating millimetre-wave gesture recognition solutions and look forward to working with industry partners to unveil more dynamic, life-changing solutions beyond CES 2022."